{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:16:50Z","timestamp":1773767810548,"version":"3.50.1"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,4,15]]},"DOI":"10.2169\/internalmedicine.1271-18","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T22:32:56Z","timestamp":1547073176000},"page":"1049-1056","source":"Crossref","is-referenced-by-count":19,"title":["Symptoms and Upper Gastrointestinal Mucosal Injury Associated with Bisphosphonate Therapy"],"prefix":"10.2169","volume":"58","author":[{"given":"Kana","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Kishino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutoshi","family":"Tokushige","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Gastroenterology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Orimo H; Japan Osteoporosis Society. The Japanese Guideline for Prevention and Treatment of Osteoporosis 2015. Life Science Publishing Co., Ltd., Tokyo, 2015 (in Japanese)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L. Gastric and esophagus events before and during treatment of osteoporosis. Calcif Tissue Int 86: 110-115, 2010.","DOI":"10.1007\/s00223-009-9323-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Peter CP, Handt LK, Smith SM, et al. Esophageal irritation due to alendronate sodium tablets. Dig Dis Sci Sep 43: 1998-2002, 1998.","DOI":"10.1023\/A:1018894827961"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Peter CP, Kindt MV, Majka JA. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats. Dig Dis Sci May 43: 1009-1015, 1998.","DOI":"10.1023\/A:1018826600877"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 335: 1016-1021, 1996.","DOI":"10.1056\/NEJM199610033351403"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kusano M, Shimoyama Y, Sugimoto S, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol 39: 888-891, 2004.","DOI":"10.1007\/s00535-004-1417-7"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Armstrong D, Benett JR, Blum AL, et al. The endoscopic assessment of esophagitis. A progress report on observer agreement. Gastroenterology 111: 85-92, 1996.","DOI":"10.1053\/gast.1996.v111.pm8698230"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Kimura K, Takemoto T. Endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 3: 87-97, 1969.","DOI":"10.1055\/s-0028-1098086"},{"key":"9","unstructured":"9. Makuuchi H. Clinical study of esophageal hiatal hernia - diagnostic criteria and degree classification of hiatal hernia-. Jpn J Gastroenterol 79: 1557-1567, 1982 (in Japanese, Abstract in English)."},{"key":"10","unstructured":"10. Sakita T, Oguro Y, Miwa T. Gastric lesions - gastric ulcers (including scars). In: Practical Training in Gastroenterological Endoscopy. Chugaiigaku Co., Ltd., Tokyo, 1981: 376-396 (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Takeshita E, Sakata Y, Hara M, et al. Higher frequency of reflux symptoms and acid-related dyspepsia in women than men regardless of endoscopic esophagitis: analysis of 3505 Japanese subjects undergoing medical health checkups. Digestion 93: 266-271, 2016.","DOI":"10.1159\/000445713"},{"key":"12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1741-7015-10-45","volume":"10","author":"N Yamamichi","year":"2012","unstructured":"12. Yamamichi N, Mochizuki S, Asada-Hirayama I, et al. Lifestyle factors affecting gastroesophageal reflux disease symptoms: a cross-sectional study of healthy 19864 adults using FSSG scores. BMC Medicine 10: 45, 2012.","journal-title":"BMC Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1741-7015","issn-type":"print"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Matsuki N, Fujita T, Watanabe N, et al. Lifestyle factors associated with gastroesophageal reflux disease in Japanese population. J Gastroenterol 48: 340-349, 2013.","DOI":"10.1007\/s00535-012-0649-1"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Okamoto K, Iwakiri R, Mori M, et al. Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8301 adult subjects. Dig Dis Sci 48: 2237-2241, 2003.","DOI":"10.1023\/B:DDAS.0000007857.15694.15"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kishimoto H, Fukunaga M, Kushida K, et al. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5 mg once-daily dosage regimen. J Bone Miner Metab 24: 405-413, 2006.","DOI":"10.1007\/s00774-006-0706-z"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Hagino H, Kishimoto H, Ohishi H, et al. Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen. Bone 59: 44-52, 2014.","DOI":"10.1016\/j.bone.2013.10.017"},{"key":"17","unstructured":"17. Miki T, Masaki H. Bisphosphonates and gastrointestinal adverse effects. Clin Calcium 19: 91-97, 2009 (in Japanese, Abstract in English)."},{"key":"18","unstructured":"18. Amagase K, Inaba A, Senta T. Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate. J Physiol Pharmacol 62: 609-618, 2011."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lanza F, Schwartz H, Sahba B, et al. An endoscopic comparison of the effect of alendronate and risedronate on upper gastrointestinal mucosae. Am J Gastroenterol 95: 3112-3117, 2000.","DOI":"10.1111\/j.1572-0241.2000.03258.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kim SH, Jeong JB, Kim JW, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. World J Gastroenterol 20: 10994-10999, 2014.","DOI":"10.3748\/wjg.v20.i31.10994"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Peng YL, Hu HY, Luo JC, et al. Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study. Osteoporosis 25: 1617-1623, 2014.","DOI":"10.1007\/s00198-014-2647-z"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kanatsu K, Aihara E, Okayama M, et al. Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate. J Gastroenterol Hepatol 19: 512-520, 2004.","DOI":"10.1111\/j.1440-1746.2003.03314.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Blank MA, Gibson GW, Myers WR, et al. Gastric damage in the rat with nitrogen-containing bisphosphonates depends on PH. Aliment Pharmacol Ther 14: 1215-1223, 2000.","DOI":"10.1046\/j.1365-2036.2000.00816.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/8\/58_1271-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,13]],"date-time":"2019-11-13T23:23:16Z","timestamp":1573687396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/8\/58_1271-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,15]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1271-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,15]]}}}